{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001724521","name":"Arcus Biosciences, Inc.","summary":"Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated small molecules and biologics for cancer and inflammatory/autoimmune diseases. Key oncology assets include casdatifan (HIF-2 inhibitor for ccRCC), quemliclustat (CD73 inhibitor for pancreatic cancer), domvanalimab (anti-TIGIT antibody for NSCLC), and zimberelimab (anti-PD-1 antibody). The company also has five preclinical inflammation programs targeting MRGPRX2, TNF, CCR6, CD89, and CD40 ligand, with first-in-clinic candidates expected in 2026.","people":[],"products":[{"name":"Casdatifan","type":"platform","description":"Oral small-molecule HIF-2 inhibitor in Phase 3 trials for clear cell renal cell carcinoma."},{"name":"Quemliclustat","type":"platform","description":"Oral small-molecule CD73 inhibitor in Phase 3 PRISM-1 trial for metastatic pancreatic cancer."},{"name":"Domvanalimab","type":"platform","description":"Anti-TIGIT antibody lacking Fc-receptor binding, in Phase 3 trials for NSCLC."},{"name":"Zimberelimab","type":"platform","description":"Anti-PD-1 antibody evaluated in combination studies in over 2600 patients across multiple cancers."},{"name":"MRGPRX2 Antagonist","type":"platform","description":"Oral small-molecule MRGPRX2 inhibitor in preclinical stage targeting chronic urticaria and atopic dermatitis."},{"name":"TNF Inhibitor","type":"platform","description":"Oral small-molecule TNFR1-selective TNF inhibitor in discovery stage targeting inflammatory/autoimmune diseases."}],"partnerships":[{"partner_name":"Gilead Sciences","partnership_type":"licensing","description":"Exclusive licenses for anti-TIGIT, anti-PD-1, and CD73 programs; options on other clinical programs; $100M annual continuation payments in 2026 and 2028.","start_date":null},{"partner_name":"Taiho Pharmaceutical","partnership_type":"licensing","description":"Exclusive option and license for casdatifan and other pipeline molecules in Japan and certain Asian countries excluding China.","start_date":null},{"partner_name":"AstraZeneca","partnership_type":"development","description":"Operationalizing eVOLVE-RCC02 Phase 1b/3 trial evaluating casdatifan with volrustomig in first-line ccRCC; recruitment temporarily paused.","start_date":null}],"affiliations":[],"origin":{"leaf":"1b697de8afaecdba45fce7c174752b5a3a588136c02254a3cf28e0e6336351d0","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"73bd0a4ec6c0666428b8e5c7941f163661144323d6ce727a8d0138fbcf670f0b","parent":"0c8d16219d2eab5ad179349a401da2a7e8fd68646fd7f0721d46a7048fbdf819","source":"0001724521-26-000009","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":414,"hourly_limit":500,"remaining":86,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}